Orpheus Uranium Limited reports a productive December quarter marked by a successful $1.66 million capital raise, completion of a major gravity survey at Mount Douglas, and ongoing progress toward regulatory approvals for advanced uranium exploration.
Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.
